All In Biotech

Drug Trial Radar · NCT05951608

A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors

A Phase Ib/II Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK112 in Patients With Advanced Malignant Tumors

Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

216

Planned (sponsor's estimate)

Start

Oct 16, 2023

Primary completion

May 1, 2026

Study completion Aug 15, 2026

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Jul 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase Ib/II Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 in combination with AK112 in Patients with Advanced Malignant Tumors

Conditions

  • Advanced Solid Tumors

Interventions

  • AK127 in combination with AK112Drug

    AK127 in combination with AK112 (administered on Day 1 of each cycle, Q3W) up to 2 years

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: From the subject signs the ICF to 30 days (AE) and 90 days (SAE) after the last dose of study treatment or initiation of other anti-tumor therapy, whichever occurs first
  2. Number of participants with a Dose Limiting Toxicity (DLT)Time frame: During the first 3 weeks
  3. Number of participants with ORRTime frame: Up to 2 years
  4. Progression-Free SurvivalTime frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.